Filing Flows › Amneal Pharmaceuticals (AMRX) › Guidance & outlook

Amneal Pharmaceuticals (AMRX) guidance and outlook

Amneal Pharmaceuticals (AMRX) raised some and lowered other parts of its guidance on Nov 3, 2026: Revenue $3.1B–$3.2B for ; EPS −$2.00 for .

Guidance and outlook

Met or beat 1 of 1 guided periods. Grey: the last range guided before the figures came out; dot: the reported figure.

Latest guidance

Metric	Period	Range	Change
Revenue	FY2026	+17%	new
Revenue		$3.1B–$3.2B	raised
EPS		−$2.00	reaffirmed

From the earnings release filed Nov 3, 2026 (8-K on EDGAR).

Amneal Pharmaceuticals' latest quarter

Amneal Pharmaceuticals, Q3 2026: revenue $863M (+10% year over year), operating margin 11.1%, net earnings $12.3M, operating cash flow $98.3M. The chart follows the revenue to costs, profit and cash.

Questions

Did Amneal Pharmaceuticals raise or lower its guidance?

Amneal Pharmaceuticals (AMRX) raised some and lowered other parts of its guidance on Nov 3, 2026: Revenue $3.1B–$3.2B for ; EPS −$2.00 for .

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.